DOI: 10.1128/CDLI.8.4.671-677.2001
Article Figures & Data
Tables
- Table 1.
Therapeutic and immunological characteristics of relevant clinical trials including IL-2 for the treatment of HIV-positive patients
Investigators (reference) Baseline CD4 count (no. of cells/mm3) Treatment CD4 increase [no. of cells/mm3 (%)] after: ARTa IL-2 treatment Simonelli et al. (58) 200–500 RTIs +60 +256 Davey et al. (13) >200 RTIs ND >200 (44), 0–200 (33) Emery et al. (19) 100–500 RTIs +153 +368 Levy et al. (36) 250–550 RTIs +55 +564 Davey et al. (14) 200–500 HAART +64 +384 Ruxrungtham et al. (55) ≥350 HAART +42 +252 Abrams et al.c ≥300 HAART +22 +276 - Table 2.
Relevant results of clinical trials investigating immunological functions in IL-2 treated, HIV-positive patientsa
Reference Cytokine production Recall antigen response HIV-specific response Apoptosis Thymic function De Paoli et al. (15) IL-2 ↑, IL-4 ↑ Blanco et al. (5) Chemok. = Kelleher et al. (30) TT =, SS = Gag =, Pol = Levy et al. (36) PPD ↑ CTL = Caggiari et al. (9) AICD = De Paoli et al. (submitted) TRECs = ↵a Symbols and abbreviations: =, not modified; ↑, increased; AICD, activation-dependent cellular death; TT, tetanus toxoid; SS, streptokinase-streptodornase; PPD, purified protein derivative; Chemok., chemokine; CTL, cytotoxic T lymphocyte.